MFDS Leadership Changes

The Ministry of Food and Drug Safety (MFDS) has replaced the leadership of two major drug review divisions. This personnel shift appears intended to strengthen rapid decision‑making in response to recent drug safety concerns and regulatory pressure. The market is watching closely to see how the new leadership will modify existing review processes.

Amgen Drug Safety Incident

Reports indicate that 20 individuals have died after taking an Amgen medication. This case highlights a serious drug safety issue, prompting a likely re‑examination of existing clinical data and additional safety monitoring. The MFDS is expected to take stringent actions to protect patients and restore confidence.

Paravillis‑Regeneron Partnership

Paravillis has entered into a partnership with Regeneron. The companies will jointly develop an obesity therapy, combining Regeneron’s antibody platform with Paravillis’s delivery technology. The collaboration is expected to generate significant synergy amid the growing obesity market.

Obesity Therapy Near Chinese Approval

The obesity therapy is on the cusp of approval in China. With a rapid rise in the number of obese patients, drug demand in the Chinese market is expanding sharply, making early approval a strategic opportunity to boost sales and strengthen local presence. At the same time, submitting data that meets the local regulatory environment remains a critical task.